Healthcare professionals working in organisations that subscribe to ScriptSwitch may register to request access – please submit your details via the ‘register’ link at the top of this page.
Category Archives: New medicines
NPC Archive Item: Low-dose anticoagulation with rivaroxaban added to standard therapy for the secondary prevention of atherothrombotic events in patients with a recent acute coronary syndrome
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 21st March 2012 The ATLAS ACS 2-TIMI 51 trial (n = 15,526) found that rivaroxaban at twice daily doses of 2.5 mg or 5 mg, in addition to standard […]
NPC Archive Item: Phase III trial tests addition of twice-daily exenatide to insulin glargine in patients with type 2 diabetes
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 23 February 2012 A randomised, double-blind, 30-week, phase III trial (n = 261) found that adding twice-daily exenatide to basal insulin therapy with insulin glargine improved HbA1c levels in […]
NPC Archive Item: Teriflunomide – another potential new oral treatment for multiple sclerosis?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 21 December 2011 Summary: Data from the two year TEMSO trial have shown that teriflunomide, a once daily oral drug for the treatment of relapsing forms of multiple sclerosis, […]
NPC Archive Item: Apixaban▼ versus warfarin in atrial fibrillation: the ARISTOTLE study in context
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 23 November 2011 The ARISTOTLE study found that apixaban▼ 5 mg twice a day reduced the risk of the composite outcome of ischaemic or haemorrhagic stroke or systemic embolism […]
NPC Archive Item: Rivaroxaban▼ non-inferior to warfarin for the prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 18 October 2011 The published data from ROCKET AF in 14,264 patients with nonvalvular atrial fibrillation (AF), who were at moderate to high risk of stroke, found that rivaroxaban […]
NPC Archive Item: Oral telaprevir▼ in patients with hepatitis C virus genotype 1 infection who did not have a sustained response to previous treatment
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 11 October 2011 The REALIZE trial (n = 663) found that the addition of oral telaprevir▼to standard therapy with peginterferon alfa-ribavirin was significantly more effective than standard treatment alone […]
NPC Archive Item: Oral telaprevir in previously untreated patients with hepatitis C virus genotype 1 infection
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 13 September 2011 The ADVANCE trial (n = 1,095) found that in previously untreated patients with genotype 1 hepatitis C infection and a baseline hepatitis C virus RNA level […]
NPC Archive Item: Once-weekly exenatide injection▼ launched in UK
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 2 September 2011 A once-weekly exenatide 2mg suspension for subcutaneous injection (Bydureon ▼®) has recently been launched for the management of type 2 diabetes. This prolonged- release formulation is […]
NPC Archive Item: Oral boceprevir▼ in patients with previously treated chronic hepatitis C virus genotype 1 infection
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 2 August 2011 The HCV RESPOND-2 trial (n=404) found that oral boceprevir given three times a day in addition to peginterferon alfa and ribavirin significantly increased rates of sustained […]